One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN. Our panel of services also include high-quality WRN protein production and established X-ray crystallography protocols.
Werner Syndrome Helicase Platform
Related Content
Introduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCEDNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCE